Medigen, Inc
Medigen, Inc. is a biomedical company dedicated to developing safe and effective vaccines against emerging infectious diseases and chronic diseases, including cancer. Founded in 2004 and headquartered in Frederick, Maryland, Medigen aims to protect human life with lifelong immunity through innovative vaccine technologies. The company focuses on applying scientific knowledge to discover, develop, and commercialize biopharmaceutical products that elicit natural, long-lasting immune responses.
Industries
Nr. of Employees
small (1-50)
Medigen, Inc
Frederick, Maryland, United States, North America
Products
Chikungunya DNA-launched live-attenuated vaccine candidate (preclinical)
A preclinical DNA-launched live-attenuated vaccine candidate evaluated in mice that elicits neutralizing antibodies and protection in challenge models.
Influenza multivalent VLP vaccine constructs (preclinical)
Recombinant multivalent virus-like particle vaccine constructs targeting multiple influenza hemagglutinin subtypes evaluated in ferret challenge models.
Lassa fever reassortant live-attenuated vaccine candidate (preclinical)
A reassortant live-attenuated vaccine candidate shown to protect mice, guinea pigs and non-human primates against multiple Lassa virus genotypes in preclinical studies.
Japanese encephalitis iDNA vaccine candidate (preclinical)
A DNA-launched live-attenuated vaccine construct encoding a synthetic live-attenuated Japanese encephalitis virus, evaluated for seroconversion and neutralizing antibody induction in mice.
Dengue and Zika iDNA vaccine candidates (preclinical)
iDNA-encoded synthetic live-attenuated vaccine plasmids designed for all four dengue serotypes and related Zika vaccine constructs, intended for direct vaccination or for cell-culture vaccine production.
RNA VLP vector cancer vaccine candidate encoding PSA (preclinical)
An RNA-based VLP vector encoding prostate-specific antigen evaluated in transgenic mouse cancer models for tumor clearance and growth delay.
Chikungunya DNA-launched live-attenuated vaccine candidate (preclinical)
A preclinical DNA-launched live-attenuated vaccine candidate evaluated in mice that elicits neutralizing antibodies and protection in challenge models.
Influenza multivalent VLP vaccine constructs (preclinical)
Recombinant multivalent virus-like particle vaccine constructs targeting multiple influenza hemagglutinin subtypes evaluated in ferret challenge models.
Lassa fever reassortant live-attenuated vaccine candidate (preclinical)
A reassortant live-attenuated vaccine candidate shown to protect mice, guinea pigs and non-human primates against multiple Lassa virus genotypes in preclinical studies.
Japanese encephalitis iDNA vaccine candidate (preclinical)
A DNA-launched live-attenuated vaccine construct encoding a synthetic live-attenuated Japanese encephalitis virus, evaluated for seroconversion and neutralizing antibody induction in mice.
Dengue and Zika iDNA vaccine candidates (preclinical)
iDNA-encoded synthetic live-attenuated vaccine plasmids designed for all four dengue serotypes and related Zika vaccine constructs, intended for direct vaccination or for cell-culture vaccine production.
RNA VLP vector cancer vaccine candidate encoding PSA (preclinical)
An RNA-based VLP vector encoding prostate-specific antigen evaluated in transgenic mouse cancer models for tumor clearance and growth delay.
Services
cGMP vaccine manufacturing and master virus bank production
cGMP production of master virus banks and vaccine manufacturing services for preclinical and clinical material.
VLP production and protein expression services
Production and expression workflows for recombinant virus-like particles and protein antigens, including multivalent VLP constructs.
Analytical and R&D support services
Ancillary R&D and analytical services including molecular biology, baculovirus preparation, electron microscopy, and sequencing-based characterization.
cGMP vaccine manufacturing and master virus bank production
cGMP production of master virus banks and vaccine manufacturing services for preclinical and clinical material.
VLP production and protein expression services
Production and expression workflows for recombinant virus-like particles and protein antigens, including multivalent VLP constructs.
Analytical and R&D support services
Ancillary R&D and analytical services including molecular biology, baculovirus preparation, electron microscopy, and sequencing-based characterization.
Expertise Areas
- Vaccine platform development
- Virus-like particle (VLP) vaccines
- DNA-launched live-attenuated vaccine design
- RNA VLP vector vaccines
Key Technologies
- Virus-like particles (VLPs)
- DNA-launched live-attenuated vaccine platform (iDNA)
- RNA VLP vectors
- Reassortant live-attenuated virus vaccines